This one-hour, on-demand, journal article-based activity presents a scoping review on the prevalence of high-potency synthetic opioids (HPSOs) in the nonmedical drug supply and their interactions with medications for opioid use disorder (MOUDs). The interactions between HPSOs and MOUDs are not yet well understood. This review examines the relationship between HPSO exposure and patient outcomes when using common MOUD treatment protocols. It also discusses the implications for clinical practice and suggests directions for future research based on the current research on patient populations impacted by HPSOs.

This 75-minute on-demand session from the ASAM 55th Annual Conference addresses pharmacotherapy options for the management of stimulant use disorders.

This 88-hour on-demand conference includes 71 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses regulatory changes and their impact on clinical outcomes for patients on methadone for OUD.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses insomnia among patients receiving medication treatment for opioid use disorder.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses career advancement and the practice of addiction medicine.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses opportunities to improve systems and processes of care for patients with methamphetamine addiction

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses bidirectional communication between the research community and addiction medicine clinicians.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses research opportunities and grant mechanisms, as well as guidance on research career pathways.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses Medicare's current coverage of substance use disorders, including some recent improvements to the program and what problems are still outstanding, as well as research on the anticipated costs and cost offsets of closing the Medicare coverage gaps.